Sensus lands Health Canada nod for its skin cancer system

November 23, 2012 by MassDevice staff

Sensus Healthcare won Health Canada approval for its device for non-surgical skin cancer treatment, following wins in the U.S. and the U.K.

Sensus Healthcare logo

Sensus Healthcare landed Health Canada approval for its SRT-100, a therapy device designed to non-surgically treat skin cancer in hospitals and private practice settings.

The SRT-100 system features the company's SharpBeam characteristics, treating targeted lesions while leaving surrounding healthy tissue intact. The device treats non-melanoma skin cancer, providing virtually pain-free treatment according to the press release.

Sign up to get our free newsletters delivered right to your inbox.

"We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice," president & CEO Joe Sardano said in prepared remarks. "We are looking forward to working with Canada's healthcare professionals."

The SRT-100 system is manufactured in the U.S. and has received FDA clearance as well as CE Mark approval.